# MeiraGTx Holdings plc (MGTX) — divestiture/asset_sale [completed]
Source: SEC API (secapi.ai) · situation sit_009b35877bfc6ad5ae0d · retrieved 2026-08-17T03:16:30.154Z

## Overview
MeiraGTx Holdings plc is a vertically integrated, clinical-stage genetic medicines company with a broad pipeline including late-stage programs for inherited retinal diseases, radiation-induced xerostomia, Parkinson's disease, and a proprietary riboswitch gene regulation technology platform.

In May 2026, MeiraGTx completed the acquisition of full rights and interests in botaretigene sparoparvovec (bota-vec) from Johnson & Johnson for a one-time $25 million upfront cash payment. J&J is eligible to receive a one-time regulatory and commercial milestone tied to U.S. approval and U.S. sales performance, plus potential mid-teens royalty on global net sales beginning in mid-2029. MeiraGTx, as the commercial manufacturer, has completed process performance qualification and holds commercial licenses for its London, U.K. manufacturing facility and its QC facility in Shannon, Ireland.

## Terms
- Counterparty: Johnson & Johnson · Deal value: $25.0M · Consideration: cash

## Key dates
- Completed 2026-05-31

## Timeline
- 2026-08-13 · 8-K (0001104659-26-095491): 8-K - MeiraGTx Holdings plc — *MeiraGTx Holdings plc is a vertically integrated, clinical-stage genetic medicines company with a broad pipeline including late-stage programs for inherited retinal diseases, radiation-induced xerostomia, Parkinson's disease, and a proprietary riboswitch gene regulation technology platform.* In May 2026, MeiraGTx completed the acquisition of full rights and interests in botaretigene sparoparvovec (bota-vec) from Johnson & Johnson for a one-time $25 million upfront cash payment. J&J is eligible to receive a one-time regulatory and commercial milestone tied to U.S. approval and U.S. sales performance, plus potential mid-teens royalty on global net sales beginning in mid-2029. MeiraGTx, as the commercial manufacturer, has completed process performance qualification and holds commercial licenses for its London, U.K. manufacturing facility and its QC facility in Shannon, Ireland.
  https://www.sec.gov/Archives/edgar/data/1735438/0001104659-26-095491.txt

## Citations
- 0001104659-26-095491 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465926095491